Vectura Group PLC (LON:VEC) announced it has signed a global out licence and development agreement with Kinaset Therapeutics Inc. to develop and commercialise VR588, a preclinical novel inhaled pan-JAK inhibitor for the prevention and treatment of severe asthma.
Pan-JAK inhibitors are mainly used for the treatment of chronic inflammatory conditions associated with an overactive immune response, while VR588 was previously developed by Vectura as part of its former speciality pharma pipeline.
READ: Vectura clinches partnership with Australian university for postpartum haemorrhage prevention formula
This agreement provides an opportunity for Vectura to realise value from its historical research and investment in VR588, whilst expanding its CDMO development services portfolio by supporting the product's further development with Kinaset, Vectura said in a statement.
Under the terms of the agreement, Kinaset's lead development programme will be an inhaled product for severe asthma delivered through a dry powder device, the pharma company said.
Vectura will provide fee for service development expertise to Kinaset to formulate this product to support Phase I studies, and ultimately through to commercialisation, while it will also grant a license to Kinaset to develop and commercialise VR588, in return for development and sales milestones, and future royalties.
US-based Kinaset may pursue VR588 products in other indications and Vectura would be entitled to milestones and royalties on future products, Vectura noted.
"We look forward to working closely with Kinaset to support their development of this product, with the potential to bring a new treatment option to asthma patients in the future," chief executive Will Downie said in a statement.
"This agreement is in line with our CDMO strategy to leverage our deep expertise, built through years of research in inhaled drug development, to help customers bring new inhaled therapies to market."